Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PSMA-venadaparib (also known as PSMA-Vena-16) is a small molecule/peptide-drug conjugate (PDC) designed for the targeted treatment of prostate cancer. It consists of a prostate-specific membrane antigen (PSMA)-targeting ligand conjugated to the potent, experimental poly(ADP-ribose) polymerase (PARP) inhibitor venadaparib via a cleavable disulfide (dithiolinker) linker. This design allows for selective delivery of venadaparib to PSMA-expressing prostate cancer cells, where intracellular glutathione (GSH) cleaves the linker to release the active PARP inhibitor. This targeted approach aims to enhance therapeutic efficacy while reducing systemic toxicities associated with conventional PARP inhibitors. Additionally, the conjugate can be radiolabeled (e.g., with Gallium-68 or Lutetium-177) for theranostic applications, enabling PET/SPECT imaging and targeted radionuclide therapy. It is being preclinically developed by researchers at the Technical University of Munich (TUM).
| Indication | Highest phase | Status |
|---|---|---|
| prostate cancer and precursor lesions | Preclinical | Active |
Every indication, with countries and timelines, is in the full profile.
| Market | Status | Year |
|---|---|---|
| United States | Not approved | — |
| European Union | Not approved | — |
| China | Not approved | — |
| Japan | Not approved | — |
Approved indications and other markets are in the full profile.
Lead indication: prostate cancer and precursor lesions
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on PSMA-venadaparib.
Work on PSMA-venadaparib? Claim this page to correct or add information. Claim this page